MedTrace Logo

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

NCT02721732 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may block specific proteins found on white blood cells which may strengthen the immune system and control tumor growth.

Conditions

  • Advanced Malignant Solid Neoplasm
  • Carcinoma of Unknown Primary
  • Metastatic Adrenal Gland Pheochromocytoma
  • Metastatic Kidney Medullary Carcinoma
  • Metastatic Malignant Germ Cell Tumor
  • Metastatic Malignant Solid Neoplasm
  • Metastatic Paraganglioma
  • Metastatic Penile Carcinoma
  • Metastatic Skin Squamous Cell Carcinoma
  • Small Cell Carcinoma
  • Stage III Adrenal Cortex Carcinoma AJCC v7
  • Stage IV Adrenal Cortex Carcinoma AJCC v7
  • Stage IV Penile Cancer AJCC v7
  • Stage IV Renal Cell Cancer AJCC v7
  • Unresectable Adrenal Gland Pheochromocytoma
  • Unresectable Paraganglioma
  • Unresectable Skin Squamous Cell Carcinoma
  • Unresectable Solid Neoplasm
  • Vascular Neoplasm

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Aung Naing · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-15
Primary Completion
2028-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02721732 on ClinicalTrials.gov